Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Carlos Gomez-Roca

Showing results (1-10 of 77) with videos related to

Pageof 8
Sort By:
Bulletin Du Cancer|March 19, 2013
[Role of high-throughput sequencing in oncology]Manuel Jorge Rodrigues, Carlos Gomez-Roca
Current Opinion in Oncology|April 9, 2014
Emerging new anticancer therapies in 2013Carlos Gomez-Roca, Jean-Pierre Delord
Cureus|December 2, 2024
Regorafenib-Triggered Hemophagocytic Lymphohistiocytosis: A Report of Two CasesIlfad Blazevic, Nadim Fares, Blandine Delaunay, et al.
Frontiers in Oncology|May 10, 2021
Radiotherapy in the Era of Immunotherapy With a Focus on Non-Small-Cell Lung Cancer: Time to Revisit Ancient Dogmas?Jonathan Khalifa, Julien Mazieres, Carlos Gomez-Roca, et al.
Clinical Lung Cancer|October 8, 2009
Pemetrexed-induced pneumonitis: a case reportYohann Loriot, Charles Ferte, Carlos Gomez-Roca, et al.
European Journal of Cancer (Oxford, England : 1990)|February 29, 2012
Prognostic value of circulating VEGFR2+ bone marrow-derived progenitor cells in patients with advanced cancerChristophe Massard, Isabelle Borget, Marie Cécile Le Deley, et al.
Cancer Chemotherapy and Pharmacology|February 23, 2018
Phase 1, open-label, dose-escalation study of sorafenib in combination with eribulin in patients with advanced, metastatic, or refractory solid tumorsFrederik Marmé, Carlos Gomez-Roca, Kristina Graudenz, et al.
Investigational New Drugs|June 6, 2009
Reversible cardiogenic shock following 5-fluorouracil infusionCharles Ferté, Carlos Gomez Roca, Yohann Loriot, et al.
Investigational New Drugs|May 9, 2020
Modernizing adverse events analysis in oncology clinical trials using alternative approaches: rationale and design of the MOTIVATE trialBastien Cabarrou, Carlos Gomez-Roca, Marie Viala, et al.
Lung Cancer (Amsterdam, Netherlands)|December 19, 2008
Telomere length, telomeric proteins and DNA damage repair proteins are differentially expressed between primary lung tumors and their adrenal metastasesChristophe M Raynaud, Olaf Mercier, Frederic Commo, et al.
Pageof 8

Showing results (1-10 of 77) with videos related to

Sort By:
Pageof 8
Bulletin Du Cancer|March 19, 2013
[Role of high-throughput sequencing in oncology]Manuel Jorge Rodrigues, Carlos Gomez-Roca
Current Opinion in Oncology|April 9, 2014
Emerging new anticancer therapies in 2013Carlos Gomez-Roca, Jean-Pierre Delord
Cureus|December 2, 2024
Regorafenib-Triggered Hemophagocytic Lymphohistiocytosis: A Report of Two CasesIlfad Blazevic, Nadim Fares, Blandine Delaunay, et al.
Frontiers in Oncology|May 10, 2021
Radiotherapy in the Era of Immunotherapy With a Focus on Non-Small-Cell Lung Cancer: Time to Revisit Ancient Dogmas?Jonathan Khalifa, Julien Mazieres, Carlos Gomez-Roca, et al.
Clinical Lung Cancer|October 8, 2009
Pemetrexed-induced pneumonitis: a case reportYohann Loriot, Charles Ferte, Carlos Gomez-Roca, et al.
European Journal of Cancer (Oxford, England : 1990)|February 29, 2012
Prognostic value of circulating VEGFR2+ bone marrow-derived progenitor cells in patients with advanced cancerChristophe Massard, Isabelle Borget, Marie Cécile Le Deley, et al.
Cancer Chemotherapy and Pharmacology|February 23, 2018
Phase 1, open-label, dose-escalation study of sorafenib in combination with eribulin in patients with advanced, metastatic, or refractory solid tumorsFrederik Marmé, Carlos Gomez-Roca, Kristina Graudenz, et al.
Investigational New Drugs|June 6, 2009
Reversible cardiogenic shock following 5-fluorouracil infusionCharles Ferté, Carlos Gomez Roca, Yohann Loriot, et al.
Investigational New Drugs|May 9, 2020
Modernizing adverse events analysis in oncology clinical trials using alternative approaches: rationale and design of the MOTIVATE trialBastien Cabarrou, Carlos Gomez-Roca, Marie Viala, et al.
Lung Cancer (Amsterdam, Netherlands)|December 19, 2008
Telomere length, telomeric proteins and DNA damage repair proteins are differentially expressed between primary lung tumors and their adrenal metastasesChristophe M Raynaud, Olaf Mercier, Frederic Commo, et al.
Pageof 8